D-Index & Metrics Best Publications

D-Index & Metrics D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines.

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 79 Citations 26,516 312 World Ranking 12265 National Ranking 6394

Overview

What is he best known for?

The fields of study he is best known for:

  • Cancer
  • Gene
  • Internal medicine

His primary scientific interests are in Melanoma, Cancer research, Pathology, Immunology and Metastasis. His research integrates issues of Cell growth, Tumor microenvironment, T cell, Cytotoxic T cell and MAPK/ERK pathway in his study of Melanoma. His Cancer research study combines topics from a wide range of disciplines, such as Cell culture, Gene knockdown, Tumor progression, Regulation of gene expression and Drug resistance.

His work deals with themes such as Neurosphere and Adult stem cell, which intersect with Pathology. Xiaowei Xu combines subjects such as Embryonic stem cell, Targeted therapy, Stem cell, Melanocyte and Unfolded protein response with his study of Immunology. The study incorporates disciplines such as Surgery, Retrospective cohort study, Anatomical pathology and Perineural invasion in addition to Metastasis.

His most cited work include:

  • Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma (1362 citations)
  • Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer (1288 citations)
  • A tumorigenic subpopulation with stem cell properties in melanomas. (1086 citations)

What are the main themes of his work throughout his whole career to date?

Xiaowei Xu spends much of his time researching Melanoma, Cancer research, Pathology, Internal medicine and Cancer. Xiaowei Xu has researched Melanoma in several fields, including Sentinel lymph node, Immune system, Immunology, Biopsy and Metastasis. His Cancer research research includes elements of Tumor progression, Cell, PI3K/AKT/mTOR pathway and Downregulation and upregulation.

His studies in Pathology integrate themes in fields like Lymphovascular invasion and Nevus. His biological study deals with issues like Endocrinology, which deal with fields such as Signal transduction. His Cancer study combines topics in areas such as Erythropoietin receptor, Erythropoietin and Combination therapy.

He most often published in these fields:

  • Melanoma (52.35%)
  • Cancer research (38.59%)
  • Pathology (25.17%)

What were the highlights of his more recent work (between 2018-2021)?

  • Melanoma (52.35%)
  • Cancer research (38.59%)
  • Internal medicine (18.46%)

In recent papers he was focusing on the following fields of study:

Xiaowei Xu mostly deals with Melanoma, Cancer research, Internal medicine, Immune system and Cancer. His Melanoma research incorporates elements of Tumor microenvironment, Biopsy, Pathology, Metastasis and Immunotherapy. Xiaowei Xu has included themes like Autophagy, Cell, Cancer cell, Neuroblastoma RAS viral oncogene homolog and Antibody in his Cancer research study.

The various areas that Xiaowei Xu examines in his Internal medicine study include Gastroenterology and Oncology. His Immune system research is multidisciplinary, incorporating elements of Cytotoxic T cell and Monoclonal antibody. As part of his studies on Cancer, Xiaowei Xu frequently links adjacent subjects like Drug resistance.

Between 2018 and 2021, his most popular works were:

  • TOX transcriptionally and epigenetically programs CD8 + T cell exhaustion (293 citations)
  • A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma (189 citations)
  • Remodeling of the Collagen Matrix in Aging Skin Promotes Melanoma Metastasis and Affects Immune Cell Motility (85 citations)

In his most recent research, the most cited papers focused on:

  • Cancer
  • Gene
  • Internal medicine

His scientific interests lie mostly in Cancer research, Melanoma, Tumor microenvironment, Immune system and Cell growth. The concepts of his Cancer research study are interwoven with issues in Autophagy, Apoptosis, Agonist, Downregulation and upregulation and Targeted therapy. His study in Melanoma is interdisciplinary in nature, drawing from both Neoadjuvant therapy, Internal medicine, Oncology and Monoclonal.

His studies deal with areas such as Wnt signaling pathway, Phenotype, Blockade, Adjuvant and Metastasis as well as Tumor microenvironment. His Cell growth research includes themes of Immune checkpoint, Cancer, Cancer cell, PD-L1 and Immunotherapy. His research in Cancer intersects with topics in Cell culture and Signal transduction.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

Christina Twyman-Saint Victor;Andrew J. Rech;Amit Maity;Ramesh Rengan;Ramesh Rengan.
Nature (2015)

1918 Citations

Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF -mutant melanoma

Gideon Bollag;Peter Hirth;James Tsai;Jiazhong Zhang.
Nature (2010)

1828 Citations

A tumorigenic subpopulation with stem cell properties in melanomas.

Dong Fang;Thiennga K. Nguyen;Kim Leishear;Rena Finko.
Cancer Research (2005)

1593 Citations

Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response

Gang Chen;Alexander C. Huang;Wei Zhang;Wei Zhang;Gao Zhang.
Nature (2018)

1386 Citations

Acquired Resistance to BRAF Inhibitors Mediated by a RAF Kinase Switch in Melanoma Can Be Overcome by Cotargeting MEK and IGF-1R/PI3K

Jessie Villanueva;Adina Vultur;John T. Lee;Rajasekharan Somasundaram.
Cancer Cell (2010)

1380 Citations

T-cell invigoration to tumour burden ratio associated with anti-PD-1 response

Alexander C. Huang;Michael A. Postow;Michael A. Postow;Robert J. Orlowski;Rosemarie Mick.
Nature (2017)

1100 Citations

Phase II, Open-Label, Single-Arm Trial of Imatinib Mesylate in Patients With Metastatic Melanoma Harboring c-Kit Mutation or Amplification

Jun Guo;Lu Si;Yan Kong;Keith T. Flaherty.
Journal of Clinical Oncology (2011)

779 Citations

TOX transcriptionally and epigenetically programs CD8 + T cell exhaustion

Omar Khan;Josephine R. Giles;Sierra McDonald;Sasikanth Manne.
Nature (2019)

626 Citations

Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients

Thomas Condamine;George A. Dominguez;Je-In Youn;Andrew V. Kossenkov.
Science immunology (2016)

488 Citations

Isolation of a Novel Population of Multipotent Adult Stem Cells from Human Hair Follicles

Hong Yu;Dong Fang;Suresh M. Kumar;Ling Li.
American Journal of Pathology (2006)

433 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Xiaowei Xu

Richard A. Scolyer

Richard A. Scolyer

Royal Prince Alfred Hospital

Publications: 125

Keith T. Flaherty

Keith T. Flaherty

Harvard University

Publications: 116

Meenhard Herlyn

Meenhard Herlyn

The Wistar Institute

Publications: 96

Georgina V. Long

Georgina V. Long

University of Sydney

Publications: 87

John F. Thompson

John F. Thompson

University of Sydney

Publications: 72

Antoni Ribas

Antoni Ribas

University of California, Los Angeles

Publications: 67

Reinhard Dummer

Reinhard Dummer

University of Zurich

Publications: 66

Grant A. McArthur

Grant A. McArthur

Peter MacCallum Cancer Centre

Publications: 60

Michael A. Davies

Michael A. Davies

The University of Texas MD Anderson Cancer Center

Publications: 57

Vernon K. Sondak

Vernon K. Sondak

University of South Florida

Publications: 50

Jeffrey A. Sosman

Jeffrey A. Sosman

Northwestern University

Publications: 50

Dirk Schadendorf

Dirk Schadendorf

University of Duisburg-Essen

Publications: 46

Jennifer A. Wargo

Jennifer A. Wargo

The University of Texas MD Anderson Cancer Center

Publications: 45

Jochen Utikal

Jochen Utikal

German Cancer Research Center

Publications: 44

Richard F. Kefford

Richard F. Kefford

Macquarie University

Publications: 42

Victor G. Prieto

Victor G. Prieto

The University of Texas MD Anderson Cancer Center

Publications: 41

Trending Scientists

Changqing Chen

Changqing Chen

Tsinghua University

Xiaohu Ge

Xiaohu Ge

Huazhong University of Science and Technology

Yun-Jiang Rao

Yun-Jiang Rao

University of Electronic Science and Technology of China

Yin Wei

Yin Wei

Chinese Academy of Sciences

Christopher L. Cahill

Christopher L. Cahill

George Washington University

Mohammad A. Omary

Mohammad A. Omary

University of North Texas

Jingbo Li

Jingbo Li

South China Normal University

Christopher R. Bowen

Christopher R. Bowen

University of Bath

Nabeel A. Affara

Nabeel A. Affara

University of Cambridge

Bernhard Radlwimmer

Bernhard Radlwimmer

German Cancer Research Center

Christopher C. Broder

Christopher C. Broder

Uniformed Services University of the Health Sciences

Catherine P. Bradshaw

Catherine P. Bradshaw

University of Virginia

Mack Roach

Mack Roach

University of California, San Francisco

Robert D. Brown

Robert D. Brown

Mayo Clinic

Ronald B. Hirschl

Ronald B. Hirschl

University of Michigan–Ann Arbor

Julien Bogousslavsky

Julien Bogousslavsky

University Hospital of Lausanne

Something went wrong. Please try again later.